Trüeb R M
Center for Dermatology and Hair Diseases Wallisellen, Zurich, Switzerland.
Skin Therapy Lett. 2010 Jul-Aug;15(7):5-7.
Chemotherapy-induced hair loss occurs with an estimated incidence of 65%. Forty-seven percent of female patients consider hair loss to be the most traumatic aspect of chemotherapy and 8% would decline chemotherapy due to fears of hair loss. At present, no approved pharmacologic intervention exists to circumvent this side-effect of anticancer treatment, though a number of agents have been investigated on the basis of the current understanding of the underlying pathobiology. Among the agents that have been evaluated, topical minoxidil was able to reduce the severity or shorten the duration, but it did not prevent hair loss. The major approach to minimize chemotherapy-induced hair loss is by scalp cooling, though most published data on this technique are of poor quality. Fortunately, the condition is usually reversible, and appropriate hair and scalp care along with temporarily wearing a wig may represent the most effective coping strategy. However, some patients may show changes in color and/or texture of regrown hair, and in limited cases the reduction in density may persist.
化疗引起的脱发发生率估计为65%。47%的女性患者认为脱发是化疗最具创伤性的方面,8%的患者会因担心脱发而拒绝化疗。目前,尚无批准的药物干预措施来规避抗癌治疗的这种副作用,尽管已根据对潜在病理生物学的当前理解对多种药物进行了研究。在已评估的药物中,局部用米诺地尔能够减轻严重程度或缩短持续时间,但不能防止脱发。尽量减少化疗引起脱发的主要方法是头皮冷却,不过关于这项技术的大多数已发表数据质量较差。幸运的是,这种情况通常是可逆的,适当的头发和头皮护理以及临时佩戴假发可能是最有效的应对策略。然而,一些患者再生头发的颜色和/或质地可能会发生变化,在少数情况下,密度降低可能会持续存在。